Neumora Therapeutics, Inc. 8-K

What Happened

• On January 5, 2026, Neumora Therapeutics, Inc. (NASDAQ: NMRA) filed a Form 8-K (Item 8.01) to report press releases announcing positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease agitation and to share pipeline updates and anticipated 2026 milestones. The press releases are attached as Exhibits 99.1 and 99.2 to the 8-K.

Key Details

• Date filed: January 5, 2026 (Form 8-K, Item 8.01).
• Program reported: NMRA-511 — Phase 1b signal-seeking study in people with Alzheimer’s disease agitation (reported as positive).
• Additional disclosure: Company issued a separate press release with broader pipeline updates and anticipated 2026 milestones.
• Exhibits: Press releases filed as Exhibits 99.1 (NMRA-511 Phase 1b Study) and 99.2 (Pipeline Updates and Anticipated Milestones).

Why It Matters

• Positive Phase 1b results are a material clinical update for Neumora’s lead program and provide investors with progress on NMRA-511’s development in Alzheimer’s agitation. The accompanying pipeline and milestone disclosures give additional visibility on the company’s near-term plans for 2026. Investors should read the attached press releases for the detailed data and timelines and monitor subsequent filings or announcements for definitive trial data, regulatory plans, or enrollment/next-step details.